# Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)

> **NCT07507188** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Yonsei University** · enrollment: 80 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Amivantamab SC + Lazertinib PO
- **DRUG:** Amivantamab SC + Chemotherapy (Carboplatin IV & Pemetrexed IV)

## Key facts

- **NCT ID:** NCT07507188
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-06
- **Primary completion:** 2031-01-31
- **Final completion:** 2031-01-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07507188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07507188, "Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07507188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*